Literature DB >> 8283256

Postoperative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990.

B J Goldsmith1, W M Wara, C B Wilson, D A Larson.   

Abstract

The authors retrospectively analyzed 140 patients treated at the University of California, San Francisco, from 1967 to 1990 to evaluate the results of radiation therapy (median 5400 cGy) given as an adjuvant to subtotal resection of intracranial meningioma. Of the 140 meningiomas, 117 were benign and 23 were malignant. The median follow-up period was 40 months. The overall survival rate at 5 years was 85% for the benign and 58% for the malignant tumor groups (p = 0.02); the 5-year progression-free survival rates were 89% and 48%, respectively (p = 0.001). For patients with benign meningioma, the 10-year overall and progression-free survival rates were 77%. An improved progression-free survival rate in that group was not related to tumor size but was associated with a younger age (p = 0.01) and treatment after 1980 with innovative technologies (p = 0.002); none of those variables affected the progression-free survival rate in the patients with malignant meningioma. Increased progression-free survival in the benign tumor group was also significantly associated with increasing the minimum radiation dose (p = 0.04). The 5-year progression-free survival rate for patients with benign meningioma treated after 1980 (when computerized tomography or magnetic resonance imaging was used for planning therapy) was 98%, as compared with 77% for patients treated before 1980 (p = 0.002). There were no second central nervous system tumors. Morbidity (3.6%) included sudden blindness or cerebral necrosis and death. When total resection of benign meningioma is not feasible, subtotal resection combined with precise treatment planning techniques and adjuvant radiation therapy can achieve results comparable to those of total resection.

Entities:  

Mesh:

Year:  1994        PMID: 8283256     DOI: 10.3171/jns.1994.80.2.0195

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  107 in total

1.  Impaired survival and long-term neurological problems in benign meningioma.

Authors:  Hanna van Alkemade; Michelle de Leau; Edith M T Dieleman; Jan W P F Kardaun; Rob van Os; W Peter Vandertop; Wouter R van Furth; Lukas J A Stalpers
Journal:  Neuro Oncol       Date:  2012-03-09       Impact factor: 12.300

Review 2.  Update on meningiomas.

Authors:  Santosh Saraf; Bridget J McCarthy; J Lee Villano
Journal:  Oncologist       Date:  2011-10-25

Review 3.  Fractionated radiotherapy for intracranial meningiomas.

Authors:  Vinai Gondi; Wolfgang A Tome; Minesh P Mehta
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

4.  Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma.

Authors:  A Gabriella Wernicke; Adam P Dicker; Michal Whiton; Jana Ivanidze; Terry Hyslop; Elizabeth H Hammond; Arie Perry; David W Andrews; Lawrence Kenyon
Journal:  Radiat Oncol       Date:  2010-05-30       Impact factor: 3.481

5.  Sellar meningiomas: an endocrinologic perspective.

Authors:  Matheni Sathananthan; Airani Sathananthan; Bernd W Scheithauer; Caterina Giannini; Fredric B Meyer; John L D Atkinson; Dana Erickson
Journal:  Pituitary       Date:  2013-06       Impact factor: 4.107

6.  Epidemiology of meningiomas post-Public Law 107-206: The Benign Brain Tumor Cancer Registries Amendment Act.

Authors:  Therese A Dolecek; Emily Van Meter Dressler; Jigisha P Thakkar; Meng Liu; Abeer Al-Qaisi; John L Villano
Journal:  Cancer       Date:  2015-04-14       Impact factor: 6.860

7.  Prospective, Randomized Study of Radiation Dose Escalation With Combined Proton-Photon Therapy for Benign Meningiomas.

Authors:  Nina N Sanford; Beow Y Yeap; Mykol Larvie; Juliane Daartz; John E Munzenrider; Norbert J Liebsch; Barbara Fullerton; Elizabeth Pan; Jay S Loeffler; Helen A Shih
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-07-12       Impact factor: 7.038

8.  Advances in multidisciplinary therapy for meningiomas.

Authors:  Priscilla K Brastianos; Evanthia Galanis; Nicholas Butowski; Jason W Chan; Ian F Dunn; Roland Goldbrunner; Christel Herold-Mende; Franziska M Ippen; Christian Mawrin; Michael W McDermott; Andrew Sloan; James Snyder; Ghazaleh Tabatabai; Marcos Tatagiba; Joerg C Tonn; Patrick Y Wen; Kenneth Aldape; Farshad Nassiri; Gelareh Zadeh; Michael D Jenkinson; David R Raleigh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 9.  Contemporary endovascular embolotherapy for meningioma.

Authors:  Gregory J Dubel; Sun Ho Ahn; Gregory M Soares
Journal:  Semin Intervent Radiol       Date:  2013-09       Impact factor: 1.513

10.  Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients.

Authors:  Beatrice Detti; Silvia Scoccianti; Vanessa Di Cataldo; Eleonora Monteleone; Samantha Cipressi; Lorenzo Bordi; Gianni Pellicanò; Davide Gadda; Calogero Saieva; Daniela Greto; Guido Pecchioli; Annamaria Buccoliero; Marco Ceroti; Franco Ammannati; Giampaolo Biti
Journal:  J Neurooncol       Date:  2013-09-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.